BCL2 and acute myeloid leukemia: The mutations or deletions of the TP53 gene are associated with the occurrence and development of a variety of tumors, which can downregulate the expression of BCL2 family pro-apoptotic proteins in AML cells, leading to the inactivation of the mitochondrial apoptotic pathway [8, 58].